TrialThe journal of prevention of Alzheimer's disease2026

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.

Michael H Davidson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.